Abstract: The present disclosure relates to a formulations and methods for transdermal delivery of a medicament through the skin of a subject. In aspects, the formulation comprises a therapeutically effective amount of a medicament and a penetrant portion in which the penetrant portion comprises: a phospholipid, a fatty acid ester formed from a low molecular weight alcohol, and a long-chain fatty acids. In some embodiments, the penetrant portion further comprises one or more of a viscosity-improving agent, a penetration enhancer, and an emulsifier.

Abstract: A non-irritating topical composition for moisturizing and cleansing the skin includes: a mixture of moisturizers and conditioning agents; a mixture of surfactants; a mixture of anti-irritant agents; and a mixture of hydrating and rejuvenation agents, in an aqueous vehicle. At least one ingredient in each of the ingredient groups consisting of moisturizers and conditioning agents, surfactants, anti-irritant agents, and hydrating and rejuvenation agents is plant-derived. The composition is essentially free from any synthetic additives or by-products. The composition has a pH in the range of 5.0-8.0.

Abstract: A composition for treating dry skin includes therapeutically active concentrations of one or more skin protecting lipids in an oleaginous base. The skin protecting lipids can include a sphingolipid and at least one oil. The composition is intended for application on the skin surrounding the eyes. The composition is configured to form a protective, occlusive layer that can moisturize the skin and reduce inflammation and itching without stinging, burning, or stripping the skin. According to an exemplary embodiment, the composition is formulated as a high viscosity ointment or gel.

Abstract: Disclosed herein is a transdermal delivery formulation for transdermal delivery of a Cannabidiol, with or without one or more additional active agents through the dermis, including the skin, nail or hair follicle of a subject, wherein the formulation comprises a) a transdermal delivery formulation in an amount less than about 60% w/w, comprising i. one or more phosphatides and ii. one or more fatty acids; b) water in an amount less than about 50% w/w, a Cannabidiol with or within one or more additional active agents.

Abstract: Embodiments include a transdermal delivery formulation and method for transdermal delivery of an active agent for systemic distribution. A formulation can be applied to skin, nail or hair follicle of a subject. After penetrating the stratum corneum, the agent can pass through other layers of skin as junctional proteins and/or acto-myosin belts between cells are modulated. The formulation can include one or more agents to treat a disease, ailment or an anesthetic to alleviate pain. Alternatively, it can include one or more nutrients, vitamins, minerals or supplements to promote health and well-being.

Abstract: Disclosed herein is a transdermal delivery formulation for transdermal delivery of cyclosporine with or without one or more additional active agents through the dermis, including the skin, nail or hair follicle of a subject. The formulation overcomes the limitations of oral administration. Specifically, embodiments include a formulation and method of delivering cyclosporine systemically into the skin to treat psoriasis or other ailments.

Abstract: Disclosed herein is a transdermal delivery formulation for transdermal delivery of an active agent through the skin, nail or hair follicle of a subject, wherein the formulation comprises a) a transdermal delivery formulation in an amount less than about 60% w/w, comprising i. one or more phosphatides, ii. glucose, and iii. one or more fatty acids; and b) water in an amount less than about 50% w/w.

Abstract: Provided herein are formulations for the transdermal administration of iron or an iron containing compound. Also provided are formulations that include iron chelators and antioxidants, and methods of using the formulations provided herein for the treatment of diseases and disorders relating to iron deficiency, anemia, and conditions associated with anemia.

Abstract: Disclosed herein is a pre-treatment and/or treatment formulation for transdermal delivery of a dermal pre-treatment agent and/or one or more dermal contouring agents through the skin of a subject, wherein the pre-treatment formulation comprises: a) a buffering agent comprising at least one carbonate salt, lysine, tris, a phosphate buffer and/or 2-imidazole-1-yl-3-ethoxycarbonylpropionic acid (IEPA), or a combination thereof in an amount between about 0.05-60% w/w; and b) a pre-treatment penetrant portion in an amount between about 40 to 99.95% w/w, and wherein the treatment formulation comprises: a) one or more acylating agents in an amount between about 0.25-25% w/w; and b) a treatment penetrant portion in an amount between about 40 to 75% w/w and methods for transdermal delivery of the pretreatment and/or treatment formulation through the skin of a subject.

Abstract: Provided herein are formulations for the safe and effective topical delivery of buffering agents. The invention includes formulations and methods to balance electrolytes, overcome cation overload, and/or deliver buffers with and without counterions that can be combined in a single use formulation or alternatively in separately applied formulations. Also provided are methods of using the formulations for the treatment of a wide variety of disorders relating to electrolyte imbalance, cation overload, or related conditions.

Abstract: A formulation for transdermal delivery of one or more ketone components through the skin of a subject, comprising: a ketone component in an amount between about 10-60% w/w; a penetrant portion in an amount less than about 60% w/w, and water in an amount less than about 50% w/w.

Abstract: Two disparate biological mechanisms which predispose to the dissemination and metastases of solid tumors is described.

Abstract: Disclosed herein is a transdermal delivery formulation for transdermal delivery of a Cannabidiol, with or without one or more additional active agents through the dermis, including the skin, nail or hair follicle of a subject, wherein the formulation comprises a) a transdermal delivery formulation in an amount less than about 60% w/w, comprising i. one or more phosphatides, ii. glucose, and iii. one or more fatty acids; b) water in an amount less than about 50% w/w, a Cannabidiol with or within one or more additional active agents.

Abstract: Disclosed herein is a transdermal delivery formulation for transdermal delivery of a Cannabidiol, with or without one or more additional active agents through the dermis, including the skin, nail or hair follicle of a subject, wherein the formulation comprises a) a transdermal delivery formulation in an amount less than about 60% w/w, comprising i. one or more phosphatides, ii. glucose, and iii. one or more fatty acids; b) water in an amount less than about 50% w/w, a Cannabidiol with or within one or more additional active agents.

Abstract: Disclosed herein is a transdermal delivery formulation for transdermal delivery of a Cannabidiol, with or without one or more additional active agents through the dermis, including the skin, nail or hair follicle of a subject, wherein the formulation comprises a) a transdermal delivery formulation in an amount less than about 60% w/w, comprising i. one or more phosphatides, ii. glucose, and iii. one or more fatty acids; b) water in an amount less than about 50% w/w, a Cannabidiol with or within one or more additional active agents.

Abstract: Two disparate biological mechanisms which predispose to the dissemination and metastases of solid tumors is described.

Abstract: Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid minors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein.

Abstract: A formulation for transdermal delivery of one or more buffering agents through the skin of a subject, comprising: a buffering agent comprising at least one carbonate salt, lysine, tris, a phosphate buffer and/or 2-imidazole-1-yl-3-ethoxycarbonylpropionic acid (IEPA), or a combination thereof in an amount between about 10-56% w/w; and a penetrant portion in an amount between about 44 to 90% w/w, wherein the penetrant portion comprises water in an amount less than about 85% w/w, and wherein the formulation comprises less than about 12% w/w lecithin.